187 results on '"Cobbaert, Christa"'
Search Results
2. Urinary beta-2 microglobulin increases whereas TIMP-2 and IGFBP7 decline after unilateral nephrectomy in healthy kidney donors
3. Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES
4. Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling
5. Validation and verification framework and data integration of biosensors and in vitro diagnostic devices: a position statement of the IFCC Committee on Mobile Health and Bioengineering in Laboratory Medicine (C-MBHLM) and the IFCC Scientific Division
6. Diagnostic accuracy of urine biomarkers for urinary tract infection in older women: a case-control study
7. Modic changes in the lumbar spine: Exploring their association with abdominal aortic calcification as a potential indicator of systemic atherosclerosis
8. An LC–MS-based designated comparison method with similar performance to the Lp(a) reference measurement procedure to guide molar Lp(a) standardization
9. Defining a metrologically traceable and sustainable calibration hierarchy of International Normalized Ratio (INR) for monitoring of vitamin K antagonist treatment in accordance with International Standard ISO 17511:2020: Communication from the IFCC-SSC/ISTH working group on PT/INR standardization
10. Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests
11. In-house diagnostic devices under the EU IVDR and unwanted side-effects of intentional transparency
12. Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
13. Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate apo(a) quantification
14. Implementing cardiovascular precision diagnostics: laboratory specialists as catalysts?
15. Current Pyuria Cutoffs Promote Inappropriate Urinary Tract Infection Diagnosis in Older Women
16. Antithrombin diagnostics by mass spectrometry: Development and analytical validation of a next-generation test
17. Influence of rosuvastatin on apolipoproteins and coagulation factor levels: Results from the STAtin Reduce Thrombophilia trial
18. ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation
19. Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests
20. Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays
21. Development of Tier 2 LC-MRM-MS protein quantification methods for liquid biopsies
22. Harmonization of indirect reference intervals calculation by the Bhattacharya method
23. Overcoming challenges regarding reference materials and regulations that influence global standardization of medical laboratory testing results
24. Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study
25. Reference intervals of urinary kidney injury biomarkers for middle-aged men and women determined by quantitative protein mass spectrometry
26. Quantitative protein mass-spectrometry requires a standardized pre-analytical phase
27. Moving average quality control of routine chemistry and hematology parameters – a toolbox for implementation
28. Comprehensive (apo)lipoprotein profiling in patients with genetic hypertriglyceridemia using LC-MS and NMR spectroscopy
29. Interference by macroprolactin in assays for prolactin: will the In Vitro Diagnostics Regulation lead to a solution at last?
30. Multiplex LC-MS/MS Testing for Early Detection of Kidney Injury: A Next-Generation Alternative to Conventional Immunoassays?
31. Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
32. Indirect determination of biochemistry reference intervals using outpatient data
33. Identifying a protein panel for early cancer detection for women at high risk for breast cancer; first results from the multicenter TESTBREAST study
34. Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry
35. Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine
36. Effect of the reaction temperature on the prothrombin time and the apparent International Normalized Ratio determined with International Standards for thromboplastins
37. Development and Provisional Validation of a Multiplex LC-MRM-MS Test for Timely Kidney Injury Detection in Urine
38. Implementation of the new EU IVD regulation – urgent initiatives are needed to avert impending crisis
39. Absence of rapid T cell control corresponds with delayed viral clearance in hospitalised COVID-19 patients
40. Bias and uncertainty of the International Normalized Ratio determined with a whole blood point-of-care prothrombin time test device by comparison to a new International Standard for thromboplastin
41. Diagnostic methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments
42. Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments
43. The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
44. Update on apolipoprotein B
45. We need to talk about the analytical performance of our laboratory developed clinical LC-MS/MS tests, and start separating the wheat from the chaff
46. The Time Has Come for Quantitative Protein Mass Spectrometry Tests That Target Unmet Clinical Needs
47. The predictive value of TIMP-2 and IGFBP7 for kidney failure and 30-day mortality after elective cardiac surgery
48. Should LC-MS/MS Be the Reference Measurement Procedure to Determine Protein Concentrations in Human Samples?
49. Designing a diagnostic Total Testing Process as a base for supporting diagnostic stewardship
50. Big data e intervalos de referencia: motivación, prácticas actuales, prerrequisitos de armonización y estandarización y futuras perspectivas en el cálculo de intervalos de referencia mediante métodos indirectos
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.